Personalized drug matching put to the test in pancreatic cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (aged 18 and over) * PC confirmed by cytology or histology * Written informed consent before any specific study procedures * Available personalized report communicating the molecular testing results and detailed treatment options * Participants must have received and progressed during or after 1 line of systemic chemotherapy in the advanced setting (gemcitabine or 5-FU based regimens) or within one year of the adjuvant/neoadjuvant treatment Notes: * In general, discontinuation of 1 drug in a multi-drug regimen and continuation of other drug(s), is considered part of the same line of treatment. Restarting the same regimen after a drug holiday or maintenance chemotherapy can also be considered part of the same line of treatment * Switching from IV (5-FU) to an oral formulation (capecitabine) of the same drug is also considered part of the same line of treatment * Minimum time from first systemic therapy for advanced PC to progression should be at least 2 months * ECOG Performance Status (PS) 0-2 * Participants must have normal organ and marrow function as defined below: * Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L * Platelet count ≥ 75 x 10⁹/L * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) * AST/ALT ≤ 5 x ULN * Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 50 mL/min (using the Cockcroft-Gault formula) * Women of childbearing potential (WOCBP) must use method(s) of contraception as indicated in the protocol * Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Exclusion Criteria: * Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results * Allergies and Adverse Drug Reaction * History of allergy to study drug components * History of severe hypersensitivity reaction to any monoclonal antibody (applicable for participants to receive a monoclonal antibody in the trial) * WOCBP who are pregnant or breastfeeding